Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

A 2-part Study Consisting of Multiple Ascending Dose (MAD) Safety Study, and a Dose-finding Masked Study to Assess the Safety and Efficacy of Intravitreal (IVT) Remigromig (EYE103) in Patients With Diabetic Macular Edema (DME) or Neovascular Age-related Macular Degeneration (NVAMD) (AMARONE)

9 octobre 2026 mis à jour par: EyeBiotech Ltd.

A 2-part Study Consisting of an Open-label Multiple Ascending Dose (MAD) Safety Study, and a Dose-finding Single-masked Comparative Safety and Preliminary Efficacy Study of Intravitreal (IVT) Remigromig in a Mixed Population of Participants With Diabetic Macular Edema (DME) or Neovascular Age-related Macular Degeneration (NVAMD)

EYE103-101 is a 2-part study assessing safety and preliminary efficacy of remigromig (EYE103) in patients with diabetic macular edema (DME) given as monotherapy or neovascular macular degeneration (NVAMD) given in combination with anti-VEGF.

In the first part, termed the multiple ascending dose (MAD) portion of study, the safety of remigromig will be assessed at escalating doses. Approximately 12 participants will be entered in this part of the study.

In the second part of the study, called the dose finding part two doses of remigromig will be selected and their effectiveness will be compared. Approximately 80 participants will be entered in this part of the study.

Aperçu de l'étude

Description détaillée

EYE103-101 is a 2-part study assessing safety and preliminary efficacy of remigromig in patients with diabetic macular edema (DME) given as monotherapy or neovascular macular degeneration (NVAMD) given in combination with anti-VEGF.

In the first part, termed the multiple ascending dose (MAD) portion of study, the safety of remigromig will be assessed at escalating doses. Approximately 12 participants will be entered in this part of the study.

In the second part of the study, called the dose finding part two doses of remigromig will be selected and their effectiveness will be compared. Approximately 80 participants will be entered in this part of the study.

Type d'étude

Interventionnel

Inscription (Réel)

33

Phase

  • Phase 2
  • La phase 1

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

      • Caba, Argentine, 1023
        • Caba, Argentina
    • Buenos Aires
      • Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentine, C1121ABB
        • Ciudad Autonoma Buenos Aires
    • PR
      • Arecibo, PR, Porto Rico, 00612
        • Arecibo, PR
      • London, Royaume-Uni, W1G7LB
        • London, UK
    • England
      • London, England, Royaume-Uni, NW10 7NS
        • London, England
    • Arizona
      • Phoenix, Arizona, États-Unis, 85032
        • Phoenix, AZ
    • California
      • Bakersfield, California, États-Unis, 93309
        • Bakersfield, CA
      • Modesto, California, États-Unis, 95356
        • Modesto, CA
      • Mountain View, California, États-Unis, 94040
        • Mountain View, CA
      • Sacramento, California, États-Unis, 95825
        • Sacramento, CA
      • Sacramento, California, États-Unis, 95841
        • Sacramento, CA
    • Colorado
      • Colorado Springs, Colorado, États-Unis, 80909
        • Colorado Springs, Colorado
      • Lakewood, Colorado, États-Unis, 80288
        • Lakewood, CO
    • Florida
      • Pompano Beach, Florida, États-Unis, 33064
        • Pompano Beach
    • Illinois
      • Lemont, Illinois, États-Unis, 60439
        • Lemont, NV
    • Maryland
      • Hagerstown, Maryland, États-Unis, 21740
        • Hagerstown, MD
    • Nevada
      • Reno, Nevada, États-Unis, 89502
        • Reno, NV
    • South Carolina
      • West Columbia, South Carolina, États-Unis, 29169
        • West Columbia, SC
    • Tennessee
      • Germantown, Tennessee, États-Unis, 38138
        • Germantown, TN
      • Knoxville, Tennessee, États-Unis, 37922
        • Knoxville, TN
      • Nashville, Tennessee, États-Unis, 37203
        • Nashville, TN
    • Texas
      • Abilene, Texas, États-Unis, 79606
        • Abilene, TX
      • Amarillo, Texas, États-Unis, 79109
        • Amarillo, TX
      • Austin, Texas, États-Unis, 78705
        • Austin, TX
      • Bellaire, Texas, États-Unis, 77401
        • Bellaire, TX
      • Dallas, Texas, États-Unis, 75231
        • Dallas, TX
      • Katy, Texas, États-Unis, 77494
        • Katy, TX
      • McAllen, Texas, États-Unis, 78503
        • McAllen, TX
      • Plano, Texas, États-Unis, 75075
        • Plano, TX
      • Round Rock, Texas, États-Unis, 78681
        • Round Rock, TX
      • San Antonio, Texas, États-Unis, 78240
        • San Antonio, TX
      • The Woodlands, Texas, États-Unis, 77384
        • The Woodlands, TX

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

50 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  • Be willing and able to understand the study procedures and the risks involved and provide written informed consent before the first study-related activity
  • DME patients must be ≥ 18 years of age, NVAMD patients must be ≥ 50 years of age
  • Diagnosis of either DME or NVAMD. DME patients must be treatment naïve. NVAMD patients can be either treatment naïve or treatment experienced.
  • DME patients must have vision loss in the study eye
  • NVAMD patients can be either treatment-naïve or treatment experienced with vision loss in the study eye

Exclusion Criteria:

  • Be pregnant or breastfeeding
  • History of cataract surgery and/or minimally invasive glaucoma surgery (MIGS) within 3 months of Screening
  • Yttrium-Aluminum Garnet (YAG) laser capsulotomy within 2 months of Screening
  • Any other condition except for DME or NVAMD or that could affect interpretation of study assessments

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation séquentielle
  • Masquage: Tripler

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Dose 1

Part 1 MAD Portion Dose 1 - Low Dose

Remigromig is a humanized antibody formulated for IVT administration

Autres noms:
  • EYE103
Expérimental: Dose 2

Part 1 MAD Portion Dose 2 - Low-Mid Dose

Remigromig is a humanized antibody formulated for IVT administration

Autres noms:
  • EYE103
Expérimental: Dose 3

Part 1 MAD Portion Dose 3 - Mid-High Dose

Remigromig is a humanized antibody formulated for IVT administration

Autres noms:
  • EYE103
Expérimental: Dose 4

Part 1 MAD Portion Dose 4 - High Dose

Remigromig is a humanized antibody formulated for IVT administration

Autres noms:
  • EYE103
Expérimental: DME Medium Dose

Part 2 Naïve DME monotherapy Medium Dose

Remigromig is a humanized antibody formulated for IVT administration

Autres noms:
  • EYE103
Expérimental: DME High Dose

Part 2 Naïve DME monotherapy High Dose

Remigromig is a humanized antibody formulated for IVT administration

Autres noms:
  • EYE103
Expérimental: Naïve NVAMD Medium Dose

Part 2 Naïve NVAMD combination therapy Medium Dose

Remigromig is a humanized antibody formulated for IVT administration

Autres noms:
  • EYE103
Expérimental: Naïve NVAMD High Dose

Part 2 Naïve NVAMD combination therapy High Dose

Remigromig is a humanized antibody formulated for IVT administration

Autres noms:
  • EYE103
Expérimental: Experienced NVAMD Medium Dose

Part 2 Experienced NVAMD combination therapy Medium Dose

Remigromig is a humanized antibody formulated for IVT administration

Autres noms:
  • EYE103
Expérimental: Experienced NVAMD High Dose

Part 2 Experienced NVAMD combination therapy High Dose

Remigromig is a humanized antibody formulated for IVT administration

Autres noms:
  • EYE103

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Number of Participants Who Experienced a Dose-limiting Toxicity (DLT)
Délai: Up to approximately 12 weeks

Systemic DLTs are defined as a Grade III (severe), IV (life threatening) or V (death related to adverse event) toxicities as defined in the National Cancer Institute (NCI) Common Toxicity Criteria, or any significant severe toxicity deemed related to study drug by the principal investigator. Ocular DLTs are defined as: loss of 4 or more lines of visual acuity, clinically significant inflammation, increase of intra-ocular pressure (IOP) from baseline of > or =15 mmHg, accelerated formation of cataract, other severe ocular abnormalities not usually seen in subjects with the condition under study, or significant retinal or choroidal vascular abnormalities seen on fluorescein angiogram deemed related to study drug by the investigator.

Up to approximately 12 weeks
Number of Participants Who Experienced an Adverse Event (AE)
Délai: Up to approximately 12 weeks

An AE is any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. Therefore, an AE can be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.

Up to approximately 12 weeks
Number of Participants Who Experienced a Serious Adverse Event (SAE)
Délai: Up to approximately 24 weeks

An SAE is defined as any adverse experience occurring at any dose that results in any of the following outcomes: Results in death; Is life threatening (immediate risk of death); results in persistent or significant disability/incapacity; requires participant hospitalization or prolongs participant hospitalization; or results in a congenital anomaly/birth defect in a neonate/infant

Up to approximately 24 weeks
Number of Participants Who Experienced Clinically Meaningful Changes in Laboratory Assessments
Délai: Baseline and Week 12

Clinical laboratory tests, including overnight fasting serum chemistry, lipid panel, hematology, and coagulation panel were collected at baseline and at week 12 study visit. Any laboratory test result considered by the investigator to be clinically significant was considered to be an AE. Clinically significant abnormal values were followed up until repeat test results return to normal, stabilize, or are no longer clinically significant.

Baseline and Week 12
Mean Change From Baseline in Best-Corrected Visual Acuity (BCVA) to Week 12 in the Study Eye - DME Participants
Délai: Baseline and Week 12

Participants' BCVA in the study eye is measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. Mean change in ETDRS letters from baseline to week 12 is presented.

Baseline and Week 12
Mean Change From Baseline in BCVA to Week 12 in the Study Eye -NVAMD Participants
Délai: Baseline and Week 12

Participants' BCVA in the study eye is measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. Mean change in ETDRS letters from baseline to week 12 is presented.

Baseline and Week 12

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Number of Participants With ETDRS BCVA Response- Treatment-Naive DME Participants
Délai: Baseline and Week 12

Participants' BCVA in the study eye is measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. The number of participants who gained 15 or more letters as measured by ETDRS from baseline in the study eye is presented.

Baseline and Week 12
Number of Participants With ETDRS BCVA Response- Treatment-Naive NVAMD Participants
Délai: Baseline and Week 12

Participants' BCVA in the study eye is measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. The number of participants who gained 15 or more letters as measured by ETDRS from baseline in the study eye is presented.

Baseline and Week 12
Mean Change in Retinal Central Subfield Thickness (CST) From Baseline in the Study Eye on Spectral Domain Optical Coherence Tomography (SDOCT): Treatment-naive DME Participants
Délai: Baseline and 12 weeks

SDOCT machines and technicians were certified at each study site by the independent reading center (IRC) prior to study start. Images were sent to the IRC for assessment. A negative change (decrease) in retinal CST from baseline indicates a decrease in retinal thickness or swelling and is considered a better outcome than no change or an increase in CST. The mean change at 12 weeks in the study eye for retinal CST from baseline is presented.

Baseline and 12 weeks
Mean Change in Retinal CST From Baseline in the Study Eye on SDOCT: Treatment-naive NVAMD Participants
Délai: Baseline and 12 weeks

SDOCT machines and technicians were certified at each study site by the independent reading center (IRC) prior to study start. Images were sent to the IRC for assessment. A negative change (decrease) in retinal CST from baseline indicates a decrease in retinal thickness or swelling and is considered a better outcome than no change or an increase in CST. The mean change at 12 weeks in the study eye for retinal CST from baseline is presented.

Baseline and 12 weeks
Number of Participants With Loss of Vision From Baseline by 15 or More Letters at Week 12-Treatment Naive DME Participants
Délai: Baseline and Week 12

Participants' BCVA in the study eye is measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. The number of participants who lost 15 or more letters as measured by ETDRS from baseline in the study eye is presented.

Baseline and Week 12
Number of Participants With Loss of Vision From Baseline by 15 or More Letters at Week 12-Treatment Naive NVAMD Participants
Délai: Baseline and Week 12

Participants' BCVA in the study eye is measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. The number of participants who lost 15 or more letters as measured by ETDRS from baseline in the study eye is presented.

Baseline and Week 12
Percent Change in Excess Retinal Fluid From Baseline at Week 12: Treatment-naive DME Participants
Délai: Baseline and Week 12

Retinal fluid in the study eye was measured by central subfield thickness (CST) as evaluated on SDOCT. SDOCT machines and technicians were certified at each study site by the independent reading center (IRC) prior to study start. Images were sent to the IRC for assessment. This outcome measure evaluates the relative change in excess CST above > 300 um from baseline to Week 12, expressed as a percentage of the baseline value. The percent change from baseline in CST in the study eye is calculated as follows: (Excess CST Baseline-Excess CST Week 12/Excess CST Baseline) *100. Positive values represent a percent reduction in excess retinal fluid (clinical improvement), and negative values represent a percent increase in excess retinal fluid (clinical worsening).

Baseline and Week 12
Percent Change in Excess Retinal Fluid From Baseline at Week 12: Treatment-naive NVAMD Participants
Délai: Baseline and Week 12

Retinal fluid in the study eye was measured by central subfield thickness (CST) as evaluated on SDOCT. SDOCT machines and technicians were certified at each study site by the independent reading center (IRC) prior to study start. Images were sent to the IRC for assessment. This outcome measure evaluates the relative change in excess CST above > 300 um from baseline to Week 12, expressed as a percentage of the baseline value. The percent change from baseline in CST in the study eye is calculated as follows: (Excess CST Baseline-Excess CST Week 12/Excess CST Baseline) *100. Positive values represent a percent reduction in excess retinal fluid (clinical improvement), and negative values represent a percent increase in excess retinal fluid (clinical worsening).

Baseline and Week 12

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

12 juin 2023

Achèvement primaire (Réel)

26 août 2024

Achèvement de l'étude (Réel)

26 août 2024

Dates d'inscription aux études

Première soumission

14 juin 2023

Première soumission répondant aux critères de contrôle qualité

14 juin 2023

Première publication (Réel)

26 juin 2023

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

3 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

9 octobre 2026

Dernière vérification

1 octobre 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

NON

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Oui

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner